Press release
World's First IASIOS Centre of Excellence in Interventional Oncology Awarded to Hôpitaux Universitaires de Strasbourg
Hôpitaux Universitaires de Strasbourg receives the world's first IASIOS Centre of Excellence seal!
Vienna, Austria, July 5, 2024 - /PressReleasePoint/ - Since its launch in April 2021, the International Accreditation System for Interventional Oncology Services (IASIOS) has rapidly expanded its network, now spanning 23 countries across 6 continents. The designation of the Hôpitaux Universitaires de Strasbourg as the world's first Centre of Excellence marks a significant milestone, highlighting their adherence to the CIRSE Standards of Quality Assurance in Interventional Oncology, a set of standards supported by 42 national and international societies, including the European Cancer Association.
The Hôpitaux Universitaires de Strasbourg was among the early adopters of the IASIOS programme, becoming the second facility in the world to achieve IASIOS Accreditation in April 2020. Their consistent maintenance of high standards and dedication to patient care has now culminated in achieving IASIOS's highest distinction, the Centre of Excellence seal. This designation required the centre to meet rigorous international standards that exceed the core criteria for IO services.
The team at the Hôpitaux Universitaires de Strasbourg demonstrated an exceptional commitment to quality patient care, facility development, and the advancement of IO as a discipline. IASIOS is proud to celebrate this global milestone with the hospital team and acknowledges their significant contribution to setting new benchmarks in IO patient care.
Prof. Afshin Gangi, Chairman of Radiology and Nuclear Medicine at the Hôpitaux Universitaires de Strasbourg, comments: "Through IASIOS, we were able to assess our department from the top down and recognize our strengths and weaknesses. This deep analysis resulted in a comprehensive improvement of patient services and safety and allowed us to provide standardized, yet personalized, treatment to each of our patients. I would like to highlight the contributions of our entire team-the IRs, nurses, radiographers, supervisors, quality control team, secretaries, and hygiene team-towards achieving and upholding the highest standards of care in IO."
For more information on becoming a part of the IASIOS network of global leaders in IO, contact the IASIOS team directly at office@iasios.org or visit their website, iasios.org. Take advantage of the membership's annual benefits programme, which offers an array of initiatives for career and professional development, networking, mentorship, workshops, promotion, and recognition. Register today at www.iasios.org!
IRAS Gmbh
c/o: Mardis Karlsdottir
Neutorgasse 9
1010 Vienna
Austria
karlsdottir@iasios.org
IASIOS is the only global accreditation system in the world specifically for interventional oncology (IO). It establishes the highest standards for patient care in IO and encourages good practice. IASIOS provides facilities with a unique opportunity to showcase their achievements and gain recognition for their IO services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release World's First IASIOS Centre of Excellence in Interventional Oncology Awarded to Hôpitaux Universitaires de Strasbourg here
News-ID: 3568397 • Views: …
More Releases from IASIOS
St. Jude Children's Research Hospital Leads the Way in Paediatric Interventional …
St. Jude Children's Research Hospital takes a groundbreaking step in paediatric oncology by enrolling in the International Accreditation System for Interventional Oncology Services (IASIOS), becoming the first paediatric hospital to pursue this prestigious accreditation.
FOR IMMEDIATE RELEASE
Providing the highest standards of care in paediatric oncology has always been central to St. Jude Children's Research Hospital's mission. We are proud to announce that St. Jude has officially enrolled in the International Accreditation…
IASIOS Extends Its Reach: First American Centre Achieves Accreditation!
The first and only accreditation system for interventional oncology (IO) achieves remarkable growth of over 150%. It continues expanding internationally with its first IASIOS Accredited Centre in North America, setting a global standard for IO.
FOR IMMEDIATE RELEASE
The International Accreditation System for Interventional Oncology Services is experiencing exponential growth exceeding 150% in the past year, making a resounding global impact. IASIOS has been at the forefront of standardising IO care worldwide,…
Interventional oncology accreditation programme IASIOS continues to reach new he …
The only accreditation system of its kind has nearly tripled its network of esteemed interventional oncology centres worldwide since launching in 2021.
The International Accreditation System for Interventional Oncology Services (IASIOS) is taking the world by storm with its exceptional growth and expansion, revolutionizing the landscape of patient care in the field of interventional oncology.
IASIOS, the esteemed membership-based accreditation, is raising the bar for quality assurance in the realm of Interventional…
More Releases for Hôpitaux
Neurofibromatosis Treatment Market to Set Phenomenal Growth by 2023
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
Neurofibromatosis Treatment Market | Future Demand & Growth Analysis with foreca …
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
Neurofibromatosis Treatment Market Research Report: Emergence of advanced techno …
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
Neurofibromatosis Treatment Market Research Report by Regional Analysis, Key Pla …
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood.
The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
Neurofibromatosis Treatment Market - Global Industry Analysis, Size, Share, Grow …
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
Neurofibromatosis Treatment Market - Global Industry Analysis, Size, Share, Grow …
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood.
Download Exclusive Sample of this Report: http://bit.ly/1UFvRln
The tumors are noncancerous (benign) in most of the cases, but in…
